TITLE

Alemtuzumab in Kidney-Transplant Recipients

AUTHOR(S)
Markmann, James F.; Fishman, Jay A.
PUB. DATE
May 2011
SOURCE
New England Journal of Medicine;5/19/2011, Vol. 364 Issue 20, p1968
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The article discusses research which compared single-dose alemtuzumab with conventional induction therapies in kidney transplantation. The first analysis compared alemtuzumab with basiliximab in low-risk transplant recipients which revealed superior prevention of biopsy-confirmed acute rejection, but at the expense of persistent leukopenia and a higher rate of serious infection. In contrast, the second analysis comparing the drug with rabbit antithymocyte globulin in high-risk recipients showed a lack of significant differences between the two.
ACCESSION #
60727972

 

Related Articles

  • Thymoglobulin Significantly More Effective than Atgam in Reversing Acute Rejection.  // Kidney;Jan/Feb99, Vol. 8 Issue 1, p35 

    Summarizes a study which aimed to compare the safety and efficacy of Thymoglobulin, a rabbit anti-human thymocyte globulin, with Atgam, a horse anti-human thymocyte globulin, for the treatment of acute rejection in renal transplant recipients (RTR). Finding that thymoglobulin was superior to...

  • Low-Dose Fluconazole Prophylaxis Safe.  // Renal & Urology News;Jun2010, Vol. 9 Issue 6, p15 

    The article reports on the findings of a study regarding the safety and efficacy of fluconazole as an antifungal prophylaxis after kidney transplantation in the U.S.

  • Nephrology: Transplantation.  // Current Medical Literature: Nephrology & Hypertension;2003, Vol. 9 Issue 2, p49 

    Presents citations and clinicians' notes on renal transplantation. Kidney transplantation with rabbit antihymocyte globulin induction and sirolimus monotherapy; Marker of humoral immunity in renal allograft rejection; Graft loss and acute coronary syndromes after renal transplantation.

  • Antithymocyte globulin best in renal transplantation.  // PharmacoEconomics & Outcomes News;5/28/2011, Issue 629, p4 

    The article focuses on a study which investigated the costs and outcomes of administering antithymocyte globulin (ATG) in renal transplant recipients.

  • Induction by anti-thymocyte globulins in kidney transplantation: a review of the literature and current usage. Malvezzi, Paolo; Jouve, Thomas; Rostaing, Lionel // Journal of Nephropathology;Oct2015, Vol. 4 Issue 4, p110 

    Context: Preventing acute rejection (AR) after kidney transplantation is of utmost importance because an AR can have a negative impact on long-term allograft survival. Evidence Acquisition: Directory of Open Access Journals (DOAJ), Google Scholar, PubMed, EBSCO, and Web of Science have been...

  • Thymoglobulin (ATG-r) Induction in Immunological High Risk Kidney Transplantation. Sopon Jirasiritham; Surasak Kantachuvejsiri; Vasant Sumethkul; Viroon Mavichak; North Techawathanawanna; Rungrote Khunprakant; Siriwan Jirasiritham; Suchin Worawichawong // Thai Journal of Surgery;Oct-Dec2012, Vol. 33 Issue 4, p139 

    Objective: To study the efficacy of the thymoglobulin (ATG-r) as an induction therapy for prevention of rejection in high risk kidney transplantation Materials and Methods: All high risk kidney transplantation patients during 2008-2010 who received thymoglobulin (ATG-r) as induction therapy were...

  • Long-term safety and efficacy of antithymocyte globulin induction: use of integrated national registry data to achieve ten-year follow-up of 10-10 Study participants. Lentine, Krista L.; Schnitzler, Mark A.; Huiling Xiao; Brennan, Daniel C. // Trials;Aug2015, Vol. 16 Issue 1, p1 

    Background: Rabbit antithymocyte globulin (rATG, Thymoglobulin®) is the most common induction immunosuppression therapy in kidney transplantation. We applied a database integration strategy to capture and compare long-term (10-year) outcome data for US participants in a clinical trial of rATG...

  • Combined Neoral/MMF Prevents Humoral Response against OKT3 mAb.  // Kidney;Jan/Feb99, Vol. 8 Issue 1, p40 

    Details the findings of a study which evaluated the impact of both CsA-Neoral (NEO), the microemulsion formulation of cyclosporine (CsA), and mycophenolate mofetil (MMF) on anti-OKT3 antibody formation in renal transplant recipients (RTR). Observation that the combination of CsA-Neoral and MMF...

  • LMW Heparin Prevents DVT after Renal Transplant.  // Kidney;Mar/Apr99, Vol. 8 Issue 2, p81 

    Presents an abstract of the study 'Efficacy and safety of low molecular weight heparin in renal transplantation,' by A.M. Alkhunaizi, A.J. Olyaei, J.M. Bary, et al.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics